Appointment of Dr Adrian Kilcoyne to SAB

Poolbeg Pharma

12/03/2026 07:00

RNS Number : 3058W

Poolbeg Pharma PLC

12 March 2026

 

 

Poolbeg Pharma plc

 

Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board

 

12 March 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board.

 

Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome ("CRS").

 

Dr Kilcoyne is currently Chief Medical Officer at Cellectis SA focusing on the development of allogeneic CAR-T therapies. He was previously Chief Medical Officer and Head of Research & Development at Celularity Inc., where he advanced oncology-focused allogeneic CAR-T and natural killer (NK) cell therapy programmes. He also served as Chief Medical Officer at Humanigen Inc., helping to build the immunology and oncology portfolios, focusing on the cytokine pathway, CAR-T therapies, immunotherapies and Antibody Drug Conjugates in haematology and solid tumours. Across his career, he has held senior leadership roles in research & development, medical affairs, commercial strategy, health economics and outcomes research at major pharmaceutical and biotechnology companies including AstraZeneca, Celgene, Sanofi, Roche, and Eli Lilly.

 

Dr Kilcoyne's clinical training began after graduating from Trinity College Dublin Medical School. He trained in Gynaecological Oncology at Hammersmith Hospital, London and later pursued advanced public health training at Oxford, earning a Master's in Public Health. He subsequently completed professional training in pharmaceutical medicine and earned an MBA from Warwick Business School.

 

Prof Luke O'Neill, Chair of the Scientific Advisory Board of Poolbeg Pharma, said: "We are delighted to welcome Dr Kilcoyne to Poolbeg's Scientific Advisory Board. He brings a wealth of experience in oncology and cell therapy drug development, combined with deep clinical insight and regulatory expertise which will be invaluable to us as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems."

 

Dr Adrian Kilcoyne, Scientific Advisory Board Member of Poolbeg Pharma, said: "I am pleased to join the Scientific Advisory Board of Poolbeg Pharma and to have the opportunity to contribute to the development of POLB 001. Having seen first-hand both the clinical impact on patients and the economic burden on healthcare systems posed by immunotherapy related CRS, I believe POLB 001 has the potential to transform the patient experience. The prevention of CRS remains a significant unmet need and addressing it may enable access for a greater number of patients to life-saving immunotherapies."    

 

 

Enquiries

 

Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO
+44 (0) 207 183 1499
ir@poolbegpharma.com
Cavendish Capital Markets Ltd (NOMAD & Joint Broker)
Geoff Nash, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Harriet Ward (ECM)
+44 (0) 207 220 0500
Shore Capital Stockbrokers Ltd (Joint Broker)
David Coaten, Harry Davies-Ball (Corporate Advisory)
 Malachy McEntyre (Corporate Broking)
+44 (0) 207 408 4090
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist
+353 (0) 1 679 6363
Optimum Strategic Communications
Nick Bastin, Vici Rabbetts, Elena Bates
+44 (0) 208 078 4357
poolbeg@optimumcomms.com

 

About Poolbeg Pharma plc 

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAGPUQAWUPQGRG